The DAAE-M score is a clinical tool for estimating risk of disease progression over five years in patients with relapsing-remitting multiple sclerosis
Use DAAE-M score in English
Other languages
Other links
- Preliminary publication
- Sample code
- DAAE score 1.0 online app
- DAAE score 1.0 paper-and-pencil version
Cite this work
Fuchs TA, Zivadinov R, Pryshchepova T, et al. Clinical risk stratification: Development and validation of the DAAE score, a tool for estimating patient risk of transition to secondary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders. 2024;89:105755. doi:10.1016/j.msard.2024.105755
Fuchs TA, Ziccardi S, Jelgerhuis J, et al. Verona validation of the DAAE score, a tool for estimating risk of clinical disease progression in people with multiple sclerosis. Multiple Sclerosis and Related Disorders. 2025;101:106586. doi: https://doi.org/10.1016/j.msard.2025.106586
Jelgerhuis JR, Uher T, Havrdova EK, et al. Clinical risk stratification: Prague validation of the DAAE score, a clinical tool for estimating risk of disesase progression in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2025;98:106423. doi: https://doi.org/10.1016/j.msard.2025.106423
About the tool
The DAAE-M score is named from factors included in the predictive model: Disease duration, Age at disease onset, Age, Expanded Disability Status Scale, and disease Modifying therapy. This work was supported by the European Committee for Treatment and Research in Multiple Sclerosis. Unspecified therapy estimates are based on international combined data from the United States (Jacobs Multiple Sclerosis Center, n=1,309), Netherlands (Multiple Sclerosis Center Amsterdam, n=877), and the MSBase multi-center international dataset (n=34,510). Low-efficacy and high-efficacy DMT risk estimates are based on a propensity-score-matched data subset from the MSBase dataset (n=5,046).
BLANK
BLANK TEXT
BLANK
BLANK TEXT
Tom A.N. Fuchs 